Adocia Announces M1Pram Clinical Data Presentation at the American Diabetes Association® 80th Scientific Sessions – Virtua...
09 June 2020 - 2:00AM
Business Wire
Regulatory News:
Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC), a
clinical stage biopharmaceutical company focused on the treatment
of diabetes and other metabolic diseases with innovative
formulations of approved proteins, announced today that an abstract
relative to bi-hormonal treatment ADO09 (M1Pram) has been accepted
for a poster presentation at the upcoming 80th Scientific Sessions
of the American Diabetes Association® (ADA). The ADA annual meeting
will take place from June 12th until 16th, 2020 as the inaugural
virtual event.
The poster presented by Adocia will describe the results of
M1Pram combination in phase 1 on type 1 diabetic patients. The
objective of this study was to compare M1Pram formulation with
Novolog®, the widely used fast acting insulin Aspart. In this
study, M1Pram offered better glycemic control with less insulin
consumption and also significant weight loss.
“We are proud to present at ADA our promising results of M1 Pram
combination. We believe that adding Pram to prandial insulin should
be the next generation of mealtime treatment”, commented Dr Olivier
Soula. “We now intend to pursue the development of M1Pram in a
three-month Phase 2 clinical trial”.
Details of the accepted abstract presented below:
Poster # 2020-LB-7039-Diabetes, ADO09, a Coformulation of
Pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose
vs. Novolog in Type 1 Diabetes (T1D)
Presenting Author: Dr. Grégory Meiffren
Session: 112-LB in category 12-E Clinical Therapeutics/New
Technology—Insulins.
About the ADA Scientific Sessions – Virtual
Experience
The American Diabetes Association’s Scientific Sessions offer
researchers and health care professionals from around the globe an
exclusive opportunity to share ideas and gain knowledge about the
recent advances in diabetes research, treatment, and care.
Attendees will have access to more than 3,000 original research
presentations, take part in thought-provoking speaking engagements
with leading diabetes experts, and expand their professional
networks. ADA Website:
https://professional.diabetes.org/scientific-sessions
About Insulin Pramlintide Combinations
Adocia has the ambition to make the insulin treatment more
physiologic by combining a well-known synergetic hormone namely
amylin analog, pramlintide. In healthy people, amylin is
co-secreted with insulin by β-islet of the pancreas to delay the
gastric emptying, to inhibit the glucagon secretion and to trigger
a satiety effect. This combination has been a challenge for a long
time as insulin and pramlintide are not compatible in water.
Adocia has made two inventions to propose a stable liquid
combination: one using BioChaperone and one using an insulin analog
stable at pH4 namely M1 (main metabolite of glargine), deamidated
A21 human insulin. The technology BioChaperone permits to combine
at pH7 either human insulin BC InsPram, or insulin analog BC
LisPram for Lispro (Humalog) and BC AsPram for Aspart
(Novolog).
Finally, Adocia has chosen to develop two pramlintide
combinations with two different insulin PK: one normal with human
insulin analog (M1Pram) and one rapid with insulin analog lispro
(BC LisPram). This 2 different insulin kinetics may be more adapted
either for the bolus injections using a pen or for the continuous
injection controlled by an insulin pump with a closed-loop
algorithm. M1Pram and BC InsPram have been both tested in type 1
diabetes patients. Adocia intends to develop the best combination
for pen and for pump to treat first type 1 diabetes and later to
treat insulin-dependent type 2 diabetes.
Last M1Pram results published last April 2020.
About Adocia
Adocia is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
therapeutic proteins and peptides for the treatment of diabetes and
metabolic diseases. In the diabetes field, Adocia’s portfolio of
injectable treatments is among the largest and most differentiated
of the industry, featuring five clinical-stage products. Adocia
aims to expand its portfolio towards the treatment of other
metabolic diseases and their comorbidities.
The proprietary BioChaperone® technological platform is designed
to enhance the effectiveness and/or safety of therapeutic proteins
while making them easier for patients to use. Adocia customizes
BioChaperone to each protein for a given application. Adocia’s
clinical pipeline includes four novel insulin formulations for the
treatment of diabetes: two ultra-rapid formulations of insulin
analog lispro (BioChaperone® Lispro U100 and U200), a combination
of basal insulin glargine and rapid-acting insulin lispro
(BioChaperone® Combo) and 2 combinations of a prandial insulin with
amylin analog pramlintide M1Pram (ADO09) and BC LisPram. It also
includes an aqueous formulation of human glucagon (BioChaperone®
Glucagon) for the treatment of hypoglycemia. Adocia preclinical
pipeline includes a combination of insulin glargine with GLP-1
receptor agonists (BioChaperone® Glargine GLP-1) for the treatment
of diabetes and a ready-to-use combination of glucagon and a GLP-1
receptor agonist (BioChaperone® Glucagon GLP1) for the treatment of
obesity. Adocia is also exploring in preclinic the potential of its
M1Pram combination to treat people with type 2 diabetes suffering
from neurological comorbidities, including Alzheimer’s disease.
In 2018, Adocia and Chinese insulin leader Tonghua Dongbao
entered a strategic alliance. In April 2018, Adocia granted Tonghua
Dongbao licenses to develop and commercialize BioChaperone Lispro
and BioChaperone Combo in China and other Asian and Middle Eastern
territories. The licensing agreements included USD 50 million
upfront and up to USD 85 million development milestones, plus
double-digit royalties on sales. In June 2018, Tonghua Dongbao
agreed to manufacture and supply active pharmaceutical ingredients
insulin lispro and insulin glargine to Adocia globally, excluding
China, to support Adocia’s portfolio development and
commercialization.
Adocia aims to deliver “Innovative medicine for everyone,
everywhere.”
To learn more about Adocia, please visit us at
www.adocia.com
Disclaimer
This press release contains certain forward-looking statements
concerning Adocia and its business. Such forward-looking statements
are based on assumptions that Adocia considers to be reasonable.
However, there can be no assurance that the estimates contained in
such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the
“Risk Factors” section of the Reference Document filed with the
French Autorité des marchés financiers on April 22, 2020 (a copy of
which is available at www.adocia.com) and to the development of
economic conditions, financial markets and the markets in which
Adocia operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Adocia or
not currently considered material by Adocia. The occurrence of all
or part of such risks could cause actual results, financial
conditions, performance or achievements of Adocia to be materially
different from such forward-looking statements.
This press release and the information contained herein do not
constitute an offer to sell or the solicitation of an offer to buy
Adocia shares in any jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200608005531/en/
Adocia Gérard Soula Chairman and CEO contactinvestisseurs@adocia.com Ph.: +33 4 72 610
610
Adocia Press Relations Europe MC Services AG
Raimund Gabriel adocia@mc-services.eu
Ph.: +49 89 210 228 0
Adocia Investor Relations USA The Ruth Group Tram
Bui tbui@theruthgroup.com Ph.: +1 646 536 7035
Adocia (EU:ADOC)
Historical Stock Chart
From Apr 2024 to May 2024
Adocia (EU:ADOC)
Historical Stock Chart
From May 2023 to May 2024